See What HealthDay Can Do For You
Contact Us

Mohs Surgery Effective for Cutaneous Leiomyosarcoma

No tumor recurrence in 11 patients treated with Mohs micrographic surgery

WEDNESDAY, June 8 (HealthDay News) -- Mohs micrographic surgery (MMS) may effectively treat and prevent tumor recurrence in patients with cutaneous leiomyosarcoma, according to a study published in the June issue of the Journal of the American Academy of Dermatology.

John Starling III, M.D., and Brett M. Coldiron, M.D., from the Skin Cancer Center in Cincinnati, reviewed the clinical characteristics and outcomes of 11 patients diagnosed at an average age of 54.5 years with cutaneous leiomyosarcoma, who were treated with MMS between 1995 and 2009. Data were collected for demographics, preoperative tumor size and location, previous treatment, number of Mohs stages necessary to obtain clearance, surgical defect size, follow-up, and recurrence.

The investigators identified three tumors on the head/neck and trunk, and five tumors on extremities. The average size of preoperative lesions was 4.69 cm², and the average surgical defect size was 14.95 cm². Tumors required an average of 2.4 MMS stages for clearance. At the time of presentation, one lesion was recurrent, and all remaining tumors were untreated. During an average follow-up of 4.47 years, no tumor recurrence was observed.

"Results of this study indicate that MMS is a useful modality for treating cutaneous leiomyosarcoma," the authors write.

Full Text (subscription or payment may be required)

Physician's Briefing